Evidence map›Paper›PMID 37301766›Full record

ArticleJournal of the American Heart Association2023

Metabolomic Profiles, Ideal Cardiovascular Health, and Risk of Heart Failure and Atrial Fibrillation: Insights From the Framingham Heart Study.

Yi Li, Ayana Gray, Liying Xue, Melissa G Farb, Nir Ayalon, Charlotte Andersson, Darae Ko, Emelia J Benjamin, Daniel Levy, Ramachandran S Vasan and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Recent advances in precision nutrition and cardiometabolic diseases.Revista espanola de cardiologia (English ed.) · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Yi LiDepartment of Biostatistics, School of Public Health Boston University Boston MA USA.ORCID 0000-0002-5544-750X
Ayana GrayHarvard University Cambridge MA USA.ORCID 0000-0002-5081-6951
Liying XueEvans Department of Medicine and Whitaker Cardiovascular Institute Boston University Chobanian & Avedisian School of Medicine Boston MA USA.ORCID 0009-0006-9281-4598
Melissa G FarbEvans Department of Medicine and Whitaker Cardiovascular Institute Boston University Chobanian & Avedisian School of Medicine Boston MA USA.ORCID 0000-0002-6811-4384
Nir AyalonSection of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center Boston MA USA.ORCID 0000-0002-0480-1249
Charlotte AnderssonSection of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center Boston MA USA.ORCID 0000-0001-6019-8627
Darae KoSection of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center Boston MA USA.ORCID 0000-0002-1174-7535
Emelia J BenjaminSection of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center Boston MA USA.ORCID 0000-0003-4076-2336
Daniel LevyPopulation Sciences Branch, Division of Intramural Research National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.ORCID 0000-0003-1843-8724
Ramachandran S VasanSection of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center Boston MA USA.ORCID 0000-0001-7357-5970
Martin G LarsonDepartment of Biostatistics Boston University School of Public Health Boston MA USA.ORCID 0000-0002-9631-1254
Jian RongDepartment of Biostatistics Boston University School of Public Health Boston MA USA.
Vanessa XanthakisSection of Preventive Medicine and Epidemiology, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston MA USA.ORCID 0000-0002-7352-621X
Chunyu LiuDepartment of Biostatistics Boston University School of Public Health Boston MA USA.ORCID 0000-0002-9160-0153
Jessica L FettermanEvans Department of Medicine and Whitaker Cardiovascular Institute Boston University Chobanian & Avedisian School of Medicine Boston MA USA.ORCID 0000-0002-9286-7538
Deepa M GopalEvans Department of Medicine and Whitaker Cardiovascular Institute Boston University Chobanian & Avedisian School of Medicine Boston MA USA.ORCID 0000-0003-3534-9360
Boston University · USHarvard University · USNational Heart Lung and Blood Institute · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
Trans-omic Analysis of Alcohol Consumption and its Relation to Cardiovascular DiseaseR01AA028263 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LIU, CHUNYU, MA, JIANTAO · 2021 to 2025
$2.6M
Determinants of obesity-associated insulin resistanceK23HL135394 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, MELISSA G · 2017 to 2021
$895k
Risk-Guided Atrial Fibrillation Surveillance in Ischemic StrokeK23HL151903 · NHLBI · HEBREW REHABILITATION CENTER FOR AGED · PI KO, DARAE · 2021 to 2025
$822k
Relations of Mitochondrial Genetic Variation and Function with Atrial FibrillationK01HL143142 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FETTERMAN, JESSICA L · 2019 to 2023
$757k
NCATS NIH HHS UL1 TR001430NHLBI NIH HHS K01 HL143142NHLBI NIH HHS K23 HL135394NHLBI NIH HHS K23 HL151903NHLBI NIH HHS R01 HL092577NIAAA NIH HHS R01 AA028263
6 · The paper itself

Abstract

Background The American Heart Association's framework "ideal cardiovascular health" (CVH) focuses on modifiable risk factors to reduce cardiovascular disease (CVD). Metabolomics provides important pathobiological insights into risk factors and CVD development. We hypothesized that metabolomic signatures associate with CVH status, and that metabolites, at least partially, mediate the association of CVH score with atrial fibrillation (AF) and heart failure (HF). Methods and Results We studied 3056 adults in the FHS (Framingham Heart Study) cohort to evaluate CVH score and incident outcomes of AF and HF. Metabolomics data were available in 2059 participants; mediation analysis was performed to evaluate the mediation of metabolites in the association of CVH score and incident AF and HF. In the smaller cohort (mean age, 54 years; 53% women), CVH score was associated with 144 metabolites, with 64 metabolites shared across key cardiometabolic components (body mass index, blood pressure, and fasting blood glucose) of the CVH score. In mediation analyses, 3 metabolites (glycerol, cholesterol ester 16:1, and phosphatidylcholine 32:1) mediated the association of CVH score with incident AF. Seven metabolites (glycerol, isocitrate, asparagine, glutamine, indole-3-proprionate, phosphatidylcholine C36:4, and lysophosphatidylcholine 18:2), partly mediated the association between CVH score and incident HF in multivariable-adjusted models. Conclusions Most metabolites that associated with CVH score were shared the most among 3 cardiometabolic components. Three main pathways: (1) alanine, glutamine, and glutamate metabolism; (2) citric acid cycle metabolism; and (3) glycerolipid metabolism mediated CVH score with HF. Metabolomics provides insights into how ideal CVH status contributes to the development of AF and HF.

Indexed as

Atrial FibrillationCardiovascular DiseasesHeart FailureAdultFemaleGlutamineGlycerolHealth StatusHumansLongitudinal StudiesMaleMetabolomicsMiddle AgedRisk FactorsUnited StatesGlutamineGlycerolatrial fibrillationCVH scoreheart failuremediation analysismetabolomics

Identifiers

PMID37301766
PMCPMC10356055
OpenAlexW4380201267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.